LifeWatch AG

EANS-Adhoc: LifeWatch AG
Announces `NiteWatch´ Home Sleep Apnea Testing Service

@@start.t1@@--------------------------------------------------------------------------------   ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide   distribution. The issuer is solely responsible for the content of this   announcement. --------------------------------------------------------------------------------@@end@@

New Products

28.07.2009

Neuhausen am Rheinfall /  Switzerland  and  Chicago  /  USA,  July   28,  2009  - LifeWatch  AG's  (SIX  Swiss  Exchange:  LIFE)  American subsidiary    LifeWatch Services, Inc., the leading provider of wireless telemedicine  services  in  the U.S., is set to expand  into the  promising  sleep  apnea  home  sleep  testing market.

LifeWatch,  the  leading  U.S.  provider  of  wireless  telemedicine services, announces the expansion of its current remote medical monitoring  services  with a sleep apnea home sleep testing  service. NiteWatch  which  will  be  launched during Q4 2009 to specific customers,  with  an  expanded  roll-out  planned  in 2010.

Sleep Apnea, which is characterized by the  temporary  suspension  of breathing during sleep for as much as 100 times a night, affects approximately 38  million individuals in the U.S. Sleep apnea is associated  with  an  increased  risk  of cardiovascular disease, stroke, high blood pressure, arrhythmias, diabetes,  and serious accidents due to fatigue and sleepiness.  Patients with untreated   sleep apnea have shown to incur double the healthcare costs of those that  have  been diagnosed  and    treated.    Despite    its    high     prevalence    and    associated complications, less than 1 in 7 patients who suffer  from  sleep  apnea  in  the U.S. have been diagnosed.

Failure to diagnose sleep apnea is in part due to the fact  that  a   patient  is required to sleep in a strange and uncomfortable environment at a sleep  lab  or clinic, while wearing an  apparatus   that  makes  the  act  of  sleeping  almost impossible.  Patients are further discouraged by  the  fact  that  sleep  clinic rooms  often   book  out  months  in  advance  due  to  the    increased    demand. Alternatively,  home  sleep  testing  (HST)  solutions  are  emerging as    the appropriate diagnostic solution for more than 95% of sleep apnea cases, as  they can be performed in the comfort of one's normal sleeping environment.  In  early 2009, Medicare issued a coverage decision memo specific to HST for  sleep  apnea diagnosis after an extensive review of clinical studies  conducted  to  validate the utilization of home sleep testing (HST). The decision declared that the  use of home sleep testing technologies  demonstrates  improved   health  outcomes  in Medicare beneficiaries  who  have  sleep  apnea and  received  the  appropriate treatment, and that these tests are thus reasonable and necessary.

"The introduction of home sleep testing will  greatly  improve  the   quality  of life of the many patients who are reluctant to go to a sleep lab",  stated  Alan Kadish, M.D. "By offering services in the comfort of their home, these  patients are almost certain of   receiving  a  correct  diagnosis  which  can  be  treated appropriately," he  added.  Dr.  Kadish  is  a  member  of   LifeWatch's  Medical Advisory Board is a fellow of both the American College of  Cardiology  and the American Heart Association and Senior Associate Chief of Cardiology at Northwestern Memorial Hospital.

Dr. Yacov Geva, Chairman and CEO of LifeWatch AG, stated,  "We  are   excited  to announce our first steps into the promising home sleep testing market,  and  are confident that our NiteWatch service will contribute  to  a  patient's  improved quality of life through earlier and more  accurate  detection  that  allows  for more appropriate treatment options".

About LifeWatch AG

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss Exchange (LIFE), Switzerland, is the leading healthcare technology and solution company, specializing in advanced telehealth systems and wireless cardiac monitoring services. LifeWatch services treat high-risk and chronically ill patients, health conscious consumers and wellness programs. LifeWatch has subsidiaries in the United States, the Netherlands, Japan, the United Kingdom, Switzerland and Israel. LifeWatch AG is the parent company of LifeWatch Services Inc., a leading US-based cardiac monitoring service provider, and manufacturer of telecardiology products. www.lifewatch.com

Sign-up for customized e-mail alerts and documentation requests is available at http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding future results of operations and financial position, business strategy and plans and objectives for future operations, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. LifeWatch AG has based these forward looking statements largely on current expectations and projections about future events and financial trends that it believes may affect the financial condition, results of operations, business strategy, short term and long term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances described may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. All forward-looking statements are based only on data available to LifeWatch AG at the time of the issue of this press release. LifeWatch AG does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS OF THE ISSUER.

-----------------------

Press Release

July 28, 2009

@@start.t2@@end of announcement                                                 euro adhoc
--------------------------------------------------------------------------------@@end@@

ots Originaltext: LifeWatch AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Kobi Ben Efraim, Chief Financial Officer, LifeWatch AG
Tel +41 52 632 00 50 | Fax +41 52 632 00 51 | E-mail kobibe@lifewatch.com

Europe
Sensus Investor and Public Relations GmbH, Zürich:
Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | E-mail lifewatch@sensus.ch

USA
Westwicke Partners
E-mail asher.dewhurst@westwicke.com

Branche: Healthcare Providers
ISIN:      CH0012815459
WKN:        1281545
Index:    SPI, SPIEX
Börsen:  Frankfurt / Open Market / XETRA
              SIX Swiss Exchange / Hauptsegment
              Berlin / free trade



Weitere Meldungen: LifeWatch AG

Das könnte Sie auch interessieren: